TEL AVIV, Israel - ColoradoDesk -- VALFIX Medical Inc. announces today an investment from California based angel group, Life Science Angels (LSA). This investment is part of the company's third investment round and concludes a meticulous due diligence process led by Dr. Gary Gershony on behalf of LSA.

VALFIX Medical is developing the first complete transcatheter solution that combines repair and replacement treatments for Heart Failure patients suffering from severe Mitral Regurgitation (MR); offering a viable alternative to open-heart surgery.

Dr. Gershony is an interventional cardiologist and a serial entrepreneur. He has been an integral part of this investment round and facilitated the connection between VALFIX Medical Inc. and the investing group that was led by LSA and included members from the Band of Angels group (BOA) and other private investors. Dr. Gershony also led the due diligence process that included experts in IP, finance, engineering and cardiology.

"I have been truly impressed by the creativity and depth of knowledge of the founders of VALFIX Medical. They have managed to push their technology forward with minimal resources and, during a relatively short time, become one of the most promising mitral technologies out there," said Dr. Gary Gershony. "I am confident in their ability to deliver a successful solution for this very important unmet clinical need."

More on Colorado Desk

• Digital Watchdog Launches New myDW Cloud Services
• Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
• Behind the Seams: CEO of Unmarked Street Launches "The Business of Apparel" for Brand Leaders
• Drone Light Shows Emerge as the New Standard in Live Event Entertainment
• Lore Link is Here to Help Organize Your Game

"We are excited about this new investment. LSA performed an extensive due diligence which we appreciate," said Eli Bar, CEO of VALFIX Medical. "This investment will help us pursue our business and product development goals."

Founded by Eli Bar, Elad Yaacoby, and Dr. Yaron Almagor, VALFIX has developed a multi-wired based technology solution that uses an innovative transcatheter system to overcome the challenges facing the treatment of Mitral Valve Regurgitation (MR).

VALFIX plans to use the proceeds from this financing round to complete the development of its innovative multi-wire technology and advance towards clinical testing.

About LSA:

Life Science Angels, Inc. was founded in 2004 by senior life science executives and experienced angel investors as a vehicle to bring angel capital to worthy early stage biotech and medical device companies.

Formally launched in January 2005 with backing from 15 industry sponsors, LSA follows a rigorous due diligence process before presenting investment opportunities to its membership. LSA also works with select angel groups, venture capitalists and outside investors to syndicate opportunities requiring larger investments. https://lifescienceangels.com/

More on Colorado Desk

• Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
• Colorado Springs: Podcast: The Parking Plan
• Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
• Get Outside Colorado! Colorado State Parks Welcome Visitors From Around the World
• AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)

About VALFIX Medical:

VALFIX Medical is developing the first complete transcatheter solution that combines repair and replacement treatments for Heart Failure patients suffering from severe Mitral Regurgitation (MR); offering a viable alternative to open-heart surgery.

To learn more about VALFIX Medical visit www.valfixmed.com or contact directly at info@valfixmed.com.